journal article·2023-05-12

Self-Assembled Proteinaceous Nanoparticles for Co-Delivery of Antigens and Cytosine Phosphoguanine (CpG) Adjuvants: Implications for Nanovaccines

Xiang Li, Chao Pan, Caixia Li, Kangfeng Wang, Jingqin Ye, Peng Sun, Yan Guo, Jun Wu, Hengliang Wang, Li Zhu

ACS Applied Nano Materials· Volume 6· Issue 9
Publisher page

Abstract

Nanotechnology has developed rapidly, giving rise to “nanovaccinology”. In particular, protein-based nanocarriers have gained widespread attention because of their excellent biocompatibility. As the development of flexible and rapid vaccines is challenging, modular extensible nanoparticles are urgently needed. In this study, a multifunctional nanocarrier capable of delivering various biomolecules (including polysaccharides, proteins, and nucleic acids) was designed by fusing the cholera toxin B subunit with streptavidin. Then, the nanocarrier was used to prepare a bioconjugate nanovaccine against S. flexneri by co-delivery of antigens and CpG adjuvants. Subsequent experimental results indicated that the nanovaccine with multiple components could stimulate both adaptive and innate immunity. Moreover, combining nanocarriers and CpG adjuvants with glycan antigens could improve the survival of vaccinated mice during the interval of two vaccination injections. The multifunctional nanocarrier and the design strategy demonstrated in this study could be utilized in the development of many other nanovaccines against infectious diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Bacteriophages and microbial interactions · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Biotechnology, Beijing, 100071, PR China

Funding

National Natural Science Foundation of China · Beijing Municipal Science and Technology Commission

References (67)

Show source-provided references
1. 10.1038/s41577-020-00479-710.1038/s41577-020-00479-7 ↗
2. 10.1016/j.vaccine.2012.08.02310.1016/j.vaccine.2012.08.023 ↗
3. 10.3389/fimmu.2018.0222410.3389/fimmu.2018.02224 ↗
4. 10.1039/C7MD00158D10.1039/C7MD00158D ↗
5. 10.1038/s41565-020-0737-y10.1038/s41565-020-0737-y ↗
6. 10.1021/acs.chemrev.5b0010910.1021/acs.chemrev.5b00109 ↗
7. 10.1016/j.jconrel.2012.01.04310.1016/j.jconrel.2012.01.043 ↗
8. 10.1016/j.jconrel.2019.04.02510.1016/j.jconrel.2019.04.025 ↗
9. 10.1007/s12274-021-3713-410.1007/s12274-021-3713-4 ↗
10. 10.1021/nl300027p10.1021/nl300027p ↗
11. 10.1128/CVI.00263-1010.1128/CVI.00263-10 ↗
12. 10.1002/advs.20210054910.1002/advs.202100549 ↗
13. 10.1038/s41467-020-16639-110.1038/s41467-020-16639-1 ↗
14. 10.1038/s41591-021-01370-110.1038/s41591-021-01370-1 ↗
15. 10.3390/vaccines902007310.3390/vaccines9020073 ↗
16. 10.1128/mBio.01813-2110.1128/mBio.01813-21 ↗
17. 10.1126/sciadv.abl601510.1126/sciadv.abl6015 ↗
18. 10.1101/2021.03.24.43652310.1101/2021.03.24.436523 ↗
19. 10.1016/S1473-3099(20)30987-710.1016/S1473-3099(20)30987-7 ↗
20. 10.1016/S1473-3099(20)30843-410.1016/S1473-3099(20)30843-4 ↗
21. 10.1371/journal.pone.003417610.1371/journal.pone.0034176 ↗
22. 10.4049/jimmunol.162.4.229110.4049/jimmunol.162.4.2291 ↗
23. 10.1016/j.biomaterials.2013.09.03810.1016/j.biomaterials.2013.09.038 ↗
24. 10.1089/vim.2007.002710.1089/vim.2007.0027 ↗
25. 10.1016/j.vaccine.2021.10.06610.1016/j.vaccine.2021.10.066 ↗
26. 10.1016/j.vaccine.2020.07.01810.1016/j.vaccine.2020.07.018 ↗
27. 10.3390/vaccines911134710.3390/vaccines9111347 ↗
28. 10.1038/386336a010.1038/386336a0 ↗
29. 10.1586/ecp.11.510.1586/ecp.11.5 ↗
30. 10.1002/adhm.20120026810.1002/adhm.201200268 ↗
31. 10.1038/nature0860410.1038/nature08604 ↗
32. 10.1002/adma.20200294010.1002/adma.202002940 ↗
33. 10.1007/s00253-019-10036-510.1007/s00253-019-10036-5 ↗
34. 10.1016/j.jconrel.2016.11.01610.1016/j.jconrel.2016.11.016 ↗
35. 10.1016/j.bios.2022.11484910.1016/j.bios.2022.114849 ↗
36. 10.1021/acsnano.1c0676810.1021/acsnano.1c06768 ↗
37. 10.1021/acs.analchem.9b0211510.1021/acs.analchem.9b02115 ↗
38. 10.4103/1735-5362.28382010.4103/1735-5362.283820 ↗
39. Amini Y. · Rep. Biochem Mol. Biol. · 2018 · 6 · 125
40. 10.3390/vaccines303057910.3390/vaccines3030579 ↗
41. 10.1128/iai.8.2.208-214.197310.1128/iai.8.2.208-214.1973 ↗
42. 10.1038/s41541-017-0037-110.1038/s41541-017-0037-1 ↗
43. 10.1128/mBio.00443-1610.1128/mBio.00443-16 ↗
44. 10.1038/s41598-020-77077-z10.1038/s41598-020-77077-z ↗
45. 10.1016/j.jbiotec.2020.01.01610.1016/j.jbiotec.2020.01.016 ↗
46. 10.1016/j.vaccine.2007.09.00810.1016/j.vaccine.2007.09.008 ↗
47. 10.1016/j.vaccine.2020.10.07710.1016/j.vaccine.2020.10.077 ↗
48. 10.1038/nri100110.1038/nri1001 ↗
49. 10.1016/j.coi.2011.08.00310.1016/j.coi.2011.08.003 ↗
50. 10.1016/S0065-2776(07)96002-210.1016/S0065-2776(07)96002-2 ↗
51. 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H ↗
52. 10.1016/j.molimm.2003.10.00510.1016/j.molimm.2003.10.005 ↗
53. 10.1016/j.iac.2021.07.00310.1016/j.iac.2021.07.003 ↗
54. 10.1016/j.fsi.2018.03.02510.1016/j.fsi.2018.03.025 ↗
55. 10.4049/jimmunol.180.2.80010.4049/jimmunol.180.2.800 ↗
56. 10.1016/j.addr.2021.11386710.1016/j.addr.2021.113867 ↗
57. 10.1016/j.nbt.2017.07.01010.1016/j.nbt.2017.07.010 ↗
58. 10.1038/nature1220210.1038/nature12202 ↗
59. 10.3390/pharmaceutics1310162110.3390/pharmaceutics13101621 ↗
60. 10.3390/molecules2709271610.3390/molecules27092716 ↗
61. 10.1016/j.cell.2019.01.04610.1016/j.cell.2019.01.046 ↗
62. 10.1016/j.nano.2016.08.03010.1016/j.nano.2016.08.030 ↗
63. 10.1007/s00018-008-7496-510.1007/s00018-008-7496-5 ↗
64. 10.1517/1742524100367774910.1517/17425241003677749 ↗
65. 10.1007/s00253-013-5232-z10.1007/s00253-013-5232-z ↗
66. 10.3390/pharmaceutics1411253910.3390/pharmaceutics14112539 ↗
67. 10.1186/s13104-017-2380-810.1186/s13104-017-2380-8 ↗